RUSSELL L CARLISLE

WESSON, MS

This page merges CMS profile IDs: 1287885, 9450869 (associated profiles published by CMS for the same provider; see the provenance section below).

General Payments — all program years on this page

$1,506,835.91

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 24
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $642,009.64 across 11 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $642,005.6910
Food and Beverage $3.951

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $642,009.6411

By program year

Program yearAmountRecords
2018 $2,805.001
2021 $301,786.004
2022 $245,107.504
2023 $315,127.774
2024 $642,009.6411

Records — PY2024 (11)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1118110339 Boehringer Ingelheim Pharmaceuticals, Inc. $3.95 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118110341 Boehringer Ingelheim Pharmaceuticals, Inc. $14,280.00 03/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110343 Boehringer Ingelheim Pharmaceuticals, Inc. $22,320.00 06/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110345 Boehringer Ingelheim Pharmaceuticals, Inc. $46,240.00 06/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110347 Boehringer Ingelheim Pharmaceuticals, Inc. $51,150.00 12/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110349 Boehringer Ingelheim Pharmaceuticals, Inc. $70,280.00 12/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110351 Boehringer Ingelheim Pharmaceuticals, Inc. $73,005.00 09/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110353 Boehringer Ingelheim Pharmaceuticals, Inc. $74,840.00 09/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110355 Boehringer Ingelheim Pharmaceuticals, Inc. $90,923.26 03/31/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110357 Boehringer Ingelheim Pharmaceuticals, Inc. $91,510.43 06/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1118110359 Boehringer Ingelheim Pharmaceuticals, Inc. $107,457.00 09/30/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
  • Merged CMS profile IDs: 1287885, 9450869

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.